### PubMed Commons comment #1

[Posted by Daniel MacArthur on June 13, 2016](http://www.ncbi.nlm.nih.gov/pubmed/27253448#cm27253448_16159)

This paper reports that an NR1H3 variant, rs61731956, encoding p.Arg415Gln, causes familial multiple sclerosis (MS) [[Wang 2016]]. We have some major concerns about the evidence for the effect of the R415Q variant on risk for MS, which rests on two pedigrees with imperfect segregation with disease.

The reported data allows us to provide an estimate of penetrance for the R415Q variant. This variant was found in 1 out of 2053 individuals in a multiple sclerosis case series, but is also seen (as the authors note in passing) in 21 individuals among the 60,706 present in the Exome Aggregation Consortium (ExAC) collection ([11-47290147-G-A](http://exac.broadinstitute.org/variant/11-47290147-G-A)). Enrichment in cases over controls is one important criterion for establishing pathogenicity of sequence variants [[MacArthur 2014], [Richards 2015]].

The ancestry distribution of the case series reported in [[Wang 2016]] is not stated, but the series was collected in Canada and appears to be of predominantly European ancestry [[Sadovnick 1998], [Traboulsee 2014]]. The 21 individuals with this variant in ExAC are all of non-Finnish European ancestry, with 66,738 non-Finnish European chromosomes having genotype calls for this variant. Thus, the variant is not significantly enriched in cases over ExAC population controls (P = .56) - indeed, its allele frequency is lower in MS cases (0.02%) than in ExAC European population controls (0.03%).

A review of lifetime risk estimates for MS found the best estimates of lifetime risk of MS to be 0.25% for women and 0.14% for men [[Alonso & Hernan 2008], see [Table 1](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109189/table/T111/)]. Using the allele frequencies observed in ExAC and in the case series, along with these estimates of lifetime risk, we can apply formulae for calculating the penetrance or lifetime risk, and confidence intervals thereof, for reportedly Mendelian variants as described in [[Kirov 2014], [Minikel 2016]]. The upper bound of the 95% confidence interval is 1.7% for women and 0.9% for men, indicating that this variant contributes extremely weakly, if at all, to MS risk.

The functional characterization of the effects of the p.Arg415Gln variant on gene function, while potentially interesting, does not provide independent support for a role of this gene in MS risk.

We urge the community to consider rigorous statistical approaches and independent replication before making strong claims of pathogenicity. In this case, publicly available data (and indeed data that are actually noted in the paper) are sufficient to strongly suggest that this variant has little or no effect on MS risk. Independent analyses of this variant in large case-control studies of MS are needed, and we look forward to seeing the results of such analyses from the MS community in the near future.

Eric Vallabh Minikel and Daniel MacArthur, Broad Institute of MIT and Harvard


[Wang 2016]: http://www.ncbi.nlm.nih.gov/pubmed/27253448 "Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, Yee  IM, de Lemos M, Greenwood T, Lee JD, Wright G, Ross CJ, Zhang S, Song W, Vilariño-Güell C. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron.  2016 Jun 1;90(5):948-54. doi: 10.1016/j.neuron.2016.04.039. PubMed PMID: 27253448."

[Richards 2015]: http://www.ncbi.nlm.nih.gov/pubmed/25741868/ "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants:  a joint consensus recommendation of the American College of Medical Genetics and  Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PubMed PMID: 25741868; PubMed Central PMCID: PMC4544753."

[MacArthur 2014]: http://www.ncbi.nlm.nih.gov/pubmed/24759409 "MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams  DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014 Apr 24;508(7497):469-76. doi: 10.1038/nature13127. PubMed PMID: 24759409; PubMed Central PMCID: PMC4180223."

[Sadovnick 1998]: http://www.ncbi.nlm.nih.gov/pubmed/9706723 "Sadovnick AD, Risch NJ, Ebers GC. Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. Can J Neurol Sci. 1998 Aug;25(3):216-21. PubMed PMID: 9706723."

[Traboulsee 2014]: http://www.ncbi.nlm.nih.gov/pubmed/24770783 "Traboulsee AL, Bernales CQ, Ross JP, Lee JD, Sadovnick AD, Vilariño-Güell C. Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression. Neurogenetics. 2014 Aug;15(3):165-9. doi: 10.1007/s10048-014-0403-3. Epub 2014 Apr 26. PubMed PMID: 24770783."

[Kirov 2014]: http://www.ncbi.nlm.nih.gov/pubmed/23992924 "Kirov G, Rees E, Walters JT, Escott-Price V, Georgieva L, Richards AL, Chambert KD, Davies G, Legge SE, Moran JL, McCarroll SA, O'Donovan MC, Owen MJ. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014 Mar 1;75(5):378-85. doi: 10.1016/j.biopsych.2013.07.022. Epub 2013 Aug 28. PubMed PMID: 23992924; PubMed Central PMCID: PMC4229045."

[Minikel 2016]: http://www.ncbi.nlm.nih.gov/pubmed/26791950 "Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, McLean CY, Tung JY, Yu LP, Gambetti P, Blevins J, Zhang S, Cohen Y, Chen W, Yamada M, Hamaguchi T, Sanjo N, Mizusawa H, Nakamura Y, Kitamoto T, Collins SJ, Boyd A, Will RG, Knight R, Ponto C, Zerr I, Kraus TF, Eigenbrod S, Giese A, Calero M, de Pedro-Cuesta J, Haïk S, Laplanche JL, Bouaziz-Amar E, Brandel JP, Capellari S, Parchi P, Poleggi A, Ladogana A, O'Donnell-Luria AH, Karczewski KJ,  Marshall JL, Boehnke M, Laakso M, Mohlke KL, Kähler A, Chambert K, McCarroll S, Sullivan PF, Hultman CM, Purcell SM, Sklar P, van der Lee SJ, Rozemuller A, Jansen C, Hofman A, Kraaij R, van Rooij JG, Ikram MA, Uitterlinden AG, van Duijn  CM; Exome Aggregation Consortium (ExAC), Daly MJ, MacArthur DG. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016 Jan 20;8(322):322ra9. doi: 10.1126/scitranslmed.aad5169. PubMed PMID: 26791950; PubMed Central PMCID: PMC4774245."

[Alonso & Hernan 2008]: http://www.ncbi.nlm.nih.gov/pubmed/18606967 "Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008 Jul 8;71(2):129-35. doi: 10.1212/01.wnl.0000316802.35974.34. Review. PubMed PMID: 18606967; PubMed Central PMCID: PMC4109189."

[Do 2011]: http://www.ncbi.nlm.nih.gov/pubmed/21738487 "Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23. PubMed PMID: 21738487; PubMed Central PMCID: PMC3121750."

[Gilks 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680457 "Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):415-6. PubMed PMID: 15680457."

[Kachergus 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15726496 "Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder  across European populations. Am J Hum Genet. 2005 Apr;76(4):672-80. Epub 2005 Feb 22. PubMed PMID: 15726496; PubMed Central PMCID: PMC1199304."

[Nichols 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680455 "Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T; Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):410-2. PubMed PMID: 15680455."

[Di Fonzo 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680456 "Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent  LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):412-5. PubMed PMID: 15680456."

[Lesage 2006]: http://www.ncbi.nlm.nih.gov/pubmed/16436781 "Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006 Jan 26;354(4):422-3. PubMed PMID: 16436781."

[Ozelius 2006]: http://www.ncbi.nlm.nih.gov/pubmed/16436782 "Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N  Engl J Med. 2006 Jan 26;354(4):424-5. PubMed PMID: 16436782."

[Elbaz 2002]: http://www.ncbi.nlm.nih.gov/pubmed/11781119 "Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002 Jan;55(1):25-31. PubMed PMID: 11781119."

[Driver 2009]: http://www.ncbi.nlm.nih.gov/pubmed/19188574/ "Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009 Feb 3;72(5):432-8. doi: 10.1212/01.wnl.0000341769.50075.bb. PubMed PMID: 19188574; PubMed Central PMCID: PMC2676726."

[Goldwurm 2007]: http://www.ncbi.nlm.nih.gov/pubmed/17215492 "Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, Pezzoli G. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology. 2007 Apr 3;68(14):1141-3. Epub 2007 Jan 10. PubMed PMID: 17215492."

